Tumor-induced suppression of antitumor reactivity and depression of TCRζ expression in tumor-draining lymph node lymphocytes: Possible relationship to the Th2 pathway

Journal of Immunotherapy

Volumn 20, Issue 2, 1997, Pages 111-122

  Fu, Eric J ^a   Arca, Marjorie J ^a   Hain, Jon M ^a   Krinock, Rob ^a   Rado, Jeff ^a   Cameron, Mark J ^a   Chang, Alfred E ^a   Sondak, Vernon K ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adoptive immunotherapy; Immunotherapy; Interleukin 4; TCR ; Tumor induced immunosuppression

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTER; IMMUNOSUPPRESSIVE TREATMENT; LUNG METASTASIS; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

EID: 0031450369     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199703000-00003     Document Type: Article

References (27)

1. Sondak VK, Wagner PD, Shu S, Chang AE. Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy. Arch Surg 1991;126:442-6.
2. Sondak VK, Tuck MK, Shu S, Chang AE. Transfer of specific tumor-induced immunosuppression by splenocytes from visceral tumor-bearing mice. Proc Am Assoc Cancer Res 1992; 33:323.
3. Hain JM, Sondak VK. Tumor-induced suppression of T cells. In: Chang AE, Shu S, eds. Immunotherapy of cancer with sensitized T lymphocytes. Georgetown, Texas: R.G. Landes, 1994:111-21.
4. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258:1795-8.
5. Ochoa AC, Longo DL. Alteration of signal transduction in T lymphocytes cells from cancer patients. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Important advances in oncology 1995. Philadelphia: J. B. Lippincott, 1995;43-54.
6. Rudd CE, Janssen O, Cai YC, da Silva AJ, Raab M, Prasad KV. Two-step TCR zeta/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases. Immunol Today 1994;15:225-34.
7. Geisler C, Kuhlmann J, Rubin B. Assembly, intracellular processing, and expression at the cell surface of the human alpha beta T cell receptor/CD3 complex: function of the CD3-zeta chain. J Immunol 1989;143:4069-77.
8. Ohno H, Aoe T, Taki S, et al. Developmental and functional impairment of T cells in mice lacking CD3 zeta chains. EMBO J 1993;12:4357-66.
9. Aoe T, Okamoto Y. Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 1995;181:1881-6.
10. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-6.
11. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993;53:5610-2.
12. Malissen M, Gillet A, Rocha B, et al. T cell development in mice lacking the CD3-zeta/eta gene. EMBO J 1993;12: 4347-55.
13. Barth RJ Jr, Bock SN, Mulé JJ, Rosenberg SA. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol 1990;144:1531-7.
14. + T cell function. Jpn J Cancer Res 1993;84:315-25.
15. Hammel JM, Tuck MK, Hain JM, Chang AE, Sondak VK. Effect of interleukin 1α on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy. J Immunotherapy 1994;16:1-12.
16. Ghosh P, Komschlies KL, Cippitelli M, et al. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 1995;87:1478-83.
17. Zea AH, Ghosh P, Longo DL, Strobl SL, Ochoa AC. Loss of Th1 phenotype in peripheral blood T cells (PBL-T) from patients with renal cell carcinoma. Proc Am Assoc Cancer Res 1995;36:2755.
18. Croft M, Swain S. Recently activated naive CD4 T cells can help resting B cells, and can produce sufficient autocrine IL-4 to drive differentiation to secretion of T helper 2-type cytokines. J Immunol 1995;154:4269-82.
19. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992;257:548-51.
20. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.
21. Nash KA, Searle RF. Induction of oncofetal antigen-specific suppressor pathways, involving Thy-1+ cells, during the early stages of tumor progression. Cell Immunol 1990;128:231-41.
22. Degwert J, Heuer J, Kolsch E. Specific in vivo suppression of lymph node cell proliferation and humoral immune responses by cloned antigen-specific T suppressor cells. J Immunol 1988;140:1448-53.
23. Wen DR, Hoon DS, Chang C, Cochran AJ. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol Immunother 1989;30:277-82.
24. Wang MB, Lichtenstein A, Mickel RA. Hierarchical immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 1991;105:517-27.
25. Franco JL, Ghosh P, Wiltrout RH, et al. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res 1995;55:3840-6.
26. Salvadori S, Gansbacher B, Zier K. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. J Immunol 1994;153:5176-83.
27. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996;2:1263-74.